TP53 and myelodysplastic syndrome: Only TP53 mutations were found to be enriched in MDS-pCT patients, while spliceosome mutations are more frequent in de novo MDS, which might partially explain the complex karyotype and unfavourable clinical outcomes of MDS-pCT patients [39].